223 related articles for article (PubMed ID: 20592492)
1. Corruption of homeostatic mechanisms in the guanylyl cyclase C signaling pathway underlying colorectal tumorigenesis.
Li P; Waldman SA
Cancer Biol Ther; 2010 Aug; 10(3):211-8. PubMed ID: 20592492
[TBL] [Abstract][Full Text] [Related]
2. Guanylyl cyclase C suppresses intestinal tumorigenesis by restricting proliferation and maintaining genomic integrity.
Li P; Schulz S; Bombonati A; Palazzo JP; Hyslop TM; Xu Y; Baran AA; Siracusa LD; Pitari GM; Waldman SA
Gastroenterology; 2007 Aug; 133(2):599-607. PubMed ID: 17681179
[TBL] [Abstract][Full Text] [Related]
3. Sex modulates intestinal transformation by the tumor-suppressor GCC.
Li P; Schulz S; Pitari GM; Waldman SA
Clin Transl Sci; 2008 Sep; 1(2):146-50. PubMed ID: 20443837
[TBL] [Abstract][Full Text] [Related]
4. Guanylyl cyclase C in colorectal cancer: susceptibility gene and potential therapeutic target.
Lin JE; Li P; Pitari GM; Schulz S; Waldman SA
Future Oncol; 2009 May; 5(4):509-22. PubMed ID: 19450179
[TBL] [Abstract][Full Text] [Related]
5. Can colorectal cancer be prevented or treated by oral hormone replacement therapy?
Li P; Lin JE; Schulz S; Pitari GM; Waldman SA
Curr Mol Pharmacol; 2009 Nov; 2(3):285-92. PubMed ID: 20021465
[TBL] [Abstract][Full Text] [Related]
6. Colorectal cancer is a paracrine deficiency syndrome amenable to oral hormone replacement therapy.
Li P; Lin JE; Snook AE; Gibbons AV; Zuzga DS; Schulz S; Pitari GM; Waldman SA
Clin Transl Sci; 2008 Sep; 1(2):163-7. PubMed ID: 19727435
[TBL] [Abstract][Full Text] [Related]
7. GCC signaling in colorectal cancer: Is colorectal cancer a paracrine deficiency syndrome?
Li P; Lin JE; Marszlowicz GP; Valentino MA; Chang C; Schulz S; Pitari GM; Waldman SA
Drug News Perspect; 2009; 22(6):313-8. PubMed ID: 19771320
[TBL] [Abstract][Full Text] [Related]
8. Loss of guanylyl cyclase C (GCC) signaling leads to dysfunctional intestinal barrier.
Han X; Mann E; Gilbert S; Guan Y; Steinbrecher KA; Montrose MH; Cohen MB
PLoS One; 2011 Jan; 6(1):e16139. PubMed ID: 21305056
[TBL] [Abstract][Full Text] [Related]
9. Intestinal GUCY2C prevents TGF-β secretion coordinating desmoplasia and hyperproliferation in colorectal cancer.
Gibbons AV; Lin JE; Kim GW; Marszalowicz GP; Li P; Stoecker BA; Blomain ES; Rattan S; Snook AE; Schulz S; Waldman SA
Cancer Res; 2013 Nov; 73(22):6654-66. PubMed ID: 24085786
[TBL] [Abstract][Full Text] [Related]
10. Intestinal cell proliferation and senescence are regulated by receptor guanylyl cyclase C and p21.
Basu N; Saha S; Khan I; Ramachandra SG; Visweswariah SS
J Biol Chem; 2014 Jan; 289(1):581-93. PubMed ID: 24217248
[TBL] [Abstract][Full Text] [Related]
11. The putative tumor suppressor Cdx2 is overexpressed by human colorectal adenocarcinomas.
Witek ME; Nielsen K; Walters R; Hyslop T; Palazzo J; Schulz S; Waldman SA
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8549-56. PubMed ID: 16361536
[TBL] [Abstract][Full Text] [Related]
12. Guanylyl cyclase C as a biomarker in colorectal cancer.
Hyslop T; Waldman SA
Biomark Med; 2013 Feb; 7(1):159-67. PubMed ID: 23387497
[TBL] [Abstract][Full Text] [Related]
13. The paracrine hormone hypothesis of colorectal cancer.
Pitari GM; Li P; Lin JE; Zuzga D; Gibbons AV; Snook AE; Schulz S; Waldman SA
Clin Pharmacol Ther; 2007 Oct; 82(4):441-7. PubMed ID: 17687268
[TBL] [Abstract][Full Text] [Related]
14. Homeostatic control of the crypt-villus axis by the bacterial enterotoxin receptor guanylyl cyclase C restricts the proliferating compartment in intestine.
Li P; Lin JE; Chervoneva I; Schulz S; Waldman SA; Pitari GM
Am J Pathol; 2007 Dec; 171(6):1847-58. PubMed ID: 17974601
[TBL] [Abstract][Full Text] [Related]
15. Guanylyl cyclase C signaling axis and colon cancer prevention.
Pattison AM; Merlino DJ; Blomain ES; Waldman SA
World J Gastroenterol; 2016 Sep; 22(36):8070-7. PubMed ID: 27688649
[TBL] [Abstract][Full Text] [Related]
16. Guanylyl cyclase C prevents colon cancer metastasis by regulating tumor epithelial cell matrix metalloproteinase-9.
Lubbe WJ; Zuzga DS; Zhou Z; Fu W; Pelta-Heller J; Muschel RJ; Waldman SA; Pitari GM
Cancer Res; 2009 Apr; 69(8):3529-36. PubMed ID: 19336567
[TBL] [Abstract][Full Text] [Related]
17. GUCY2C: at the intersection of obesity and cancer.
Kim GW; Lin JE; Waldman SA
Trends Endocrinol Metab; 2013 Apr; 24(4):165-73. PubMed ID: 23375388
[TBL] [Abstract][Full Text] [Related]
18. Guanylyl cyclase C is a selective marker for metastatic colorectal tumors in human extraintestinal tissues.
Carrithers SL; Barber MT; Biswas S; Parkinson SJ; Park PK; Goldstein SD; Waldman SA
Proc Natl Acad Sci U S A; 1996 Dec; 93(25):14827-32. PubMed ID: 8962140
[TBL] [Abstract][Full Text] [Related]
19. The hormone receptor GUCY2C suppresses intestinal tumor formation by inhibiting AKT signaling.
Lin JE; Li P; Snook AE; Schulz S; Dasgupta A; Hyslop TM; Gibbons AV; Marszlowicz G; Pitari GM; Waldman SA
Gastroenterology; 2010 Jan; 138(1):241-54. PubMed ID: 19737566
[TBL] [Abstract][Full Text] [Related]
20. APC-β-catenin-TCF signaling silences the intestinal guanylin-GUCY2C tumor suppressor axis.
Blomain ES; Rappaport JA; Pattison AM; Bashir B; Caparosa E; Stem J; Snook AE; Waldman SA
Cancer Biol Ther; 2020 May; 21(5):441-451. PubMed ID: 32037952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
